[go: up one dir, main page]

AR132574A2 - UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA - Google Patents

UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA

Info

Publication number
AR132574A2
AR132574A2 ARP240101109A ARP240101109A AR132574A2 AR 132574 A2 AR132574 A2 AR 132574A2 AR P240101109 A ARP240101109 A AR P240101109A AR P240101109 A ARP240101109 A AR P240101109A AR 132574 A2 AR132574 A2 AR 132574A2
Authority
AR
Argentina
Prior art keywords
isoform
tgf
receptor
ligand
fused
Prior art date
Application number
ARP240101109A
Other languages
English (en)
Inventor
Ricardo Alfredo Dewey
Zamora Benito Jorge Velasco
Tania Melina Rodrguez
Alejandra Carrea
Andrea Nancy CHISARI
Marcelo Javier Perone
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Fund Articular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Fund Articular filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR132574A2 publication Critical patent/AR132574A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una isoforma del receptor II de TGF b que comprende una secuencia de alrededor de 80 aminoácidos y carece del dominio transmembrana; en donde la isoforma es agonista de TGFb-1. La isoforma comprende a la secuencia de aminoácidos SEQ ID Nº 12. La isoforma puede tener la secuencia de aminoácidos SEQ ID Nº 2 o secuencias que tienen al menos un 85% de identidad de secuencia con la secuencia SEQ ID Nº 2.
ARP240101109A 2013-12-19 2024-05-02 UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA AR132574A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917974P 2013-12-19 2013-12-19

Publications (1)

Publication Number Publication Date
AR132574A2 true AR132574A2 (es) 2025-07-16

Family

ID=53403721

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
ARP200101538A AR119056A2 (es) 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
ARP240101109A AR132574A2 (es) 2013-12-19 2024-05-02 UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
ARP200101538A AR119056A2 (es) 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada

Country Status (5)

Country Link
US (1) US10233227B2 (es)
EP (1) EP3082846B1 (es)
AR (3) AR098827A1 (es)
ES (1) ES2749615T3 (es)
WO (1) WO2015095628A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107780A1 (es) * 2016-11-14 2018-06-06 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Método para determinar la actividad de enfermedades autoinmunes y kit
JP7319992B2 (ja) 2018-03-09 2023-08-02 アジェナス インコーポレイテッド 抗ｃｄ７３抗体およびそれらの使用方法
CN110372800B (zh) 2019-08-27 2022-06-07 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1994009815A1 (en) 1992-10-29 1994-05-11 Celtrix Pharmaceuticals, Inc. USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030028905A1 (en) * 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
WO2003060075A2 (en) 2001-12-21 2003-07-24 The Regents Of The University Of California USE OF SOLUBLE TYPE II TGF-β RECEPTOR TO SUPPRESS PANCREATIC CANCER GROWTH AND METASTASIS
JP2010529859A (ja) 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途

Also Published As

Publication number Publication date
US10233227B2 (en) 2019-03-19
US20160318989A1 (en) 2016-11-03
WO2015095628A8 (en) 2016-09-29
AR119056A2 (es) 2021-11-17
EP3082846A1 (en) 2016-10-26
AR098827A1 (es) 2016-06-15
WO2015095628A1 (en) 2015-06-25
EP3082846B1 (en) 2019-07-17
ES2749615T3 (es) 2020-03-23
EP3082846A4 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
AR132574A2 (es) UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA
EA201691111A1 (ru) Химерные белки фактора viii и их применение
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
ES2545895T3 (es) Proteína de fusión anticancerígena
CL2017001070A1 (es) Variantes de interferon a2b
IL258102A (en) Immunomodulatory transmembrane proteins containing domain variants of the immunoglobulin superfamily, nucleic acids encoding them, vectors and cells expressing them and uses thereof
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
MX382929B (es) Polipéptido heterodimerizado.
EA201491277A1 (ru) Противораковый слитый белок
CO6700829A2 (es) Moduladores novedosos y métodos de uso
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
EA201401211A1 (ru) Улучшенные варианты фермента химозина
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR101146A1 (es) Proteína con actividad xilanasa
MX2018002616A (es) Proteina de fusion.
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
WO2014162007A3 (en) Thymic stromal lymphopoietin fragments and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure